Susquehanna International Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-177,200
Closed -$6.67M 13721
2021
Q1
$6.67M Buy
177,200
+114,700
+184% +$2.86M ﹤0.01% 3405
2020
Q4
$1.06M Buy
+62,500
New +$783K ﹤0.01% 6584
2020
Q2
Sell
-14,000
Closed -$32K 11343
2020
Q1
$32K Buy
+14,000
New +$59.4K ﹤0.01% 9819
2019
Q4
Sell
-122,200
Closed -$474K 11062
2019
Q3
$474K Buy
122,200
+90,900
+290% +$499K ﹤0.01% 7422
2019
Q2
$189K Buy
31,300
+1,300
+4% +$12.4K ﹤0.01% 9173
2019
Q1
$402K Sell
30,000
-7,600
-20% -$86.7K ﹤0.01% 6690
2018
Q4
$350K Sell
37,600
-37,300
-50% -$444K ﹤0.01% 6728
2018
Q3
$1.04M Buy
74,900
+34,800
+87% +$518K ﹤0.01% 5138
2018
Q2
$634K Sell
40,100
-14,400
-26% -$251K ﹤0.01% 6336
2018
Q1
$936K Buy
54,500
+10,100
+23% +$197K ﹤0.01% 5379
2017
Q4
$973K Sell
44,400
-31,200
-41% -$1M ﹤0.01% 5294
2017
Q3
$3.09M Buy
75,600
+39,200
+108% +$1.23M ﹤0.01% 3189
2017
Q2
$1.1M Buy
36,400
+2,100
+6% +$65.5K ﹤0.01% 5067
2017
Q1
$1.24M Buy
+34,300
New +$1.51M ﹤0.01% 4685
2016
Q4
Sell
-55,200
Closed -$2.9M 10385
2016
Q3
$2.9M Sell
55,200
-10,100
-15% -$482K ﹤0.01% 2959
2016
Q2
$2.7M Sell
65,300
-4,200
-6% -$183K ﹤0.01% 3084
2016
Q1
$2.82M Sell
69,500
-55,700
-44% -$1.91M ﹤0.01% 3156
2015
Q4
$5.2M Buy
125,200
+106,900
+584% +$3.58M ﹤0.01% 2494
2015
Q3
$282K Buy
18,300
+1,700
+10% +$36.5K ﹤0.01% 8146
2015
Q2
$412K Buy
+16,600
New +$370K ﹤0.01% 7997

Susquehanna International Group's FPRX Position: Q2 2021 in Review

Susquehanna International Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 29,986 shares — an estimated $1.13M sold.

Susquehanna International Group first reported a position in FPRX in Q1 2015 and held it in 10 quarters. The position peaked at $1.13M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Susquehanna International Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Susquehanna International Group sold 29,986 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.13M.
  • Susquehanna International Group first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
  • Susquehanna International Group's Five Prime Therapeutics, Inc. position peaked at $1.13M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Susquehanna International Group's 13F filing for Q2 2021, filed 11 Aug 2021.